June 2023 – Cantex Pharmaceuticals announced that it obtained an exclusive worldwide license from Georgetown University for intellectual property related to the potential use of azeliragon to treat, prevent or alleviate cancer-treatment related cognitive decline.
May 2023 – Cantex Pharmaceuticals announced today that the USPTO has issued U.S. Patent No. 11,648,235, titled “Treatment of Glioblastoma,” with claims to a method of treating glioblastoma with azeliragon. This patent will expire in 2042.
April 2023 – Cantex Pharmaceuticals and Michigan Medicine, a part of the University of Michigan, announced the initiation of a randomized double-blind, placebo-controlled, multicenter, phase 2/3 clinical study to evaluate the safety and efficacy of azeliragon in decreasing the incidence of acute kidney injury and other life-threatening complications in patients hospitalized for COVID-19.
READ ALL NEWS